These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 19094058

  • 1. Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats: new insights into the role of delta receptors in parkinsonism.
    Mabrouk OS, Volta M, Marti M, Morari M.
    J Neurochem; 2008 Dec; 107(6):1647-59. PubMed ID: 19094058
    [Abstract] [Full Text] [Related]

  • 2. The novel delta opioid receptor agonist UFP-512 dually modulates motor activity in hemiparkinsonian rats via control of the nigro-thalamic pathway.
    Mabrouk OS, Marti M, Salvadori S, Morari M.
    Neuroscience; 2009 Dec 01; 164(2):360-9. PubMed ID: 19729051
    [Abstract] [Full Text] [Related]

  • 3. Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism.
    Mabrouk OS, Viaro R, Volta M, Ledonne A, Mercuri N, Morari M.
    J Neurosci; 2014 Sep 24; 34(39):12953-62. PubMed ID: 25253844
    [Abstract] [Full Text] [Related]

  • 4. The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway.
    Marti M, Trapella C, Viaro R, Morari M.
    J Neurosci; 2007 Feb 07; 27(6):1297-307. PubMed ID: 17287504
    [Abstract] [Full Text] [Related]

  • 5. The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.
    Marti M, Trapella C, Morari M.
    J Neurochem; 2008 Dec 07; 107(6):1683-96. PubMed ID: 19014386
    [Abstract] [Full Text] [Related]

  • 6. Pallidal origin of GABA release within the substantia nigra pars reticulata during high-frequency stimulation of the subthalamic nucleus.
    Windels F, Carcenac C, Poupard A, Savasta M.
    J Neurosci; 2005 May 18; 25(20):5079-86. PubMed ID: 15901790
    [Abstract] [Full Text] [Related]

  • 7. Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity.
    Volta M, Viaro R, Trapella C, Marti M, Morari M.
    Exp Neurol; 2011 Mar 18; 228(1):126-37. PubMed ID: 21215744
    [Abstract] [Full Text] [Related]

  • 8. Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism.
    Fantin M, Auberson YP, Morari M.
    J Neurochem; 2008 Jul 18; 106(2):957-68. PubMed ID: 18435828
    [Abstract] [Full Text] [Related]

  • 9. Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease.
    Ochi M, Shiozaki S, Kase H.
    Neuroscience; 2004 Jul 18; 127(1):223-31. PubMed ID: 15219684
    [Abstract] [Full Text] [Related]

  • 10. Motor activity-induced dopamine release in the substantia nigra is regulated by muscarinic receptors.
    Andersson DR, Björnsson E, Bergquist F, Nissbrandt H.
    Exp Neurol; 2010 Jan 18; 221(1):251-9. PubMed ID: 19944096
    [Abstract] [Full Text] [Related]

  • 11. Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway.
    Yamamura S, Ohoyama K, Nagase H, Okada M.
    Neuropharmacology; 2009 Sep 18; 57(3):322-31. PubMed ID: 19482038
    [Abstract] [Full Text] [Related]

  • 12. Differential role of GABAA and GABAB receptors in two distinct output stations of the rat striatum: studies on the substantia nigra pars reticulata and the globus pallidus.
    Ikeda H, Kotani A, Koshikawa N, Cools AR.
    Neuroscience; 2010 Apr 28; 167(1):31-9. PubMed ID: 20132872
    [Abstract] [Full Text] [Related]

  • 13. The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats.
    Konieczny J, Wardas J, Kuter K, Pilc A, Ossowska K.
    Neuroscience; 2007 Mar 16; 145(2):611-20. PubMed ID: 17224239
    [Abstract] [Full Text] [Related]

  • 14. Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice.
    Mabrouk OS, Marti M, Morari M.
    Neuroscience; 2010 Mar 10; 166(1):40-8. PubMed ID: 20006677
    [Abstract] [Full Text] [Related]

  • 15. Interactions between dopamine D1 receptors and gamma-aminobutyric acid mechanisms in substantia nigra pars reticulata of the rat: neurochemical and behavioral studies.
    Trevitt T, Carlson B, Correa M, Keene A, Morales M, Salamone JD.
    Psychopharmacology (Berl); 2002 Jan 10; 159(3):229-37. PubMed ID: 11862355
    [Abstract] [Full Text] [Related]

  • 16. The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.
    Lindenbach D, Conti MM, Ostock CY, George JA, Goldenberg AA, Melikhov-Sosin M, Nuss EE, Bishop C.
    J Neurosci; 2016 Sep 21; 36(38):9873-87. PubMed ID: 27656025
    [Abstract] [Full Text] [Related]

  • 17. Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease.
    Pisanò CA, Brugnoli A, Novello S, Caccia C, Keywood C, Melloni E, Vailati S, Padoani G, Morari M.
    Neuropharmacology; 2020 May 01; 167():108006. PubMed ID: 32086070
    [Abstract] [Full Text] [Related]

  • 18. Increased responsivity of glutamate release from the substantia nigra pars reticulata to striatal NMDA receptor blockade in a model of Parkinson's disease. A dual probe microdialysis study in hemiparkinsonian rats.
    Marti M, Sbrenna S, Fuxe K, Bianchi C, Beani L, Morari M.
    Eur J Neurosci; 2000 May 01; 12(5):1848-50. PubMed ID: 10792462
    [Abstract] [Full Text] [Related]

  • 19. The delta-opioid receptor agonist SNC80 [(+)-4-[alpha(R)-alpha-[(2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl]-(3-methoxybenzyl)-N,N-diethylbenzamide] synergistically enhances the locomotor-activating effects of some psychomotor stimulants, but not direct dopamine agonists, in rats.
    Jutkiewicz EM, Baladi MG, Folk JE, Rice KC, Woods JH.
    J Pharmacol Exp Ther; 2008 Feb 01; 324(2):714-24. PubMed ID: 17986650
    [Abstract] [Full Text] [Related]

  • 20. Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease.
    Hille CJ, Fox SH, Maneuf YP, Crossman AR, Brotchie JM.
    Exp Neurol; 2001 Nov 01; 172(1):189-98. PubMed ID: 11681851
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.